Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 10 |
| List of Tables | 10 | 1 |
| List of Figures | 11 | 1 |
| Introduction | 12 | 1 |
| Global Markets Direct Report Coverage | 12 | 1 |
| Keratoconjunctivitis sicca (Dry Eye) Overview | 13 | 1 |
| Therapeutics Development | 14 | 2 |
| Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) Overview | 14 | 1 |
| Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) Comparative Analysis | 15 | 1 |
| Keratoconjunctivitis sicca (Dry Eye) Therapeutics under Development by Companies | 16 | 4 |
| Keratoconjunctivitis sicca (Dry Eye) Therapeutics under Investigation by Universities/Institutes | 20 | 1 |
| Keratoconjunctivitis sicca (Dry Eye) Pipeline Products Glance | 21 | 4 |
| Late Stage Products | 21 | 1 |
| Clinical Stage Products | 22 | 1 |
| Early Stage Products | 23 | 1 |
| Unknown Stage Products | 24 | 1 |
| Keratoconjunctivitis sicca (Dry Eye) Products under Development by Companies | 25 | 4 |
| Keratoconjunctivitis sicca (Dry Eye) Products under Investigation by Universities/Institutes | 29 | 1 |
| Keratoconjunctivitis sicca (Dry Eye) Companies Involved in Therapeutics Development | 30 | 38 |
| AB2 Bio Ltd. | 30 | 1 |
| Allergan Plc | 31 | 1 |
| Ascendia Pharmaceuticals LLC | 32 | 1 |
| Chong Kun Dang Pharmaceutical Corp. | 33 | 1 |
| Digna Biotech, S.L. | 34 | 1 |
| Dompe Farmaceutici S.p.A. | 35 | 1 |
| HanAll Biopharma Co., Ltd. | 36 | 1 |
| Herantis Pharma Plc | 37 | 1 |
| Huons Co., Ltd. | 38 | 1 |
| InSite Vision Incorporated | 39 | 1 |
| Kala Pharmaceuticals, Inc. | 40 | 1 |
| Kissei Pharmaceutical Co., Ltd. | 41 | 1 |
| KPI Therapeutics, Inc. | 42 | 1 |
| Kukje Pharmaceutical Industry Co., Ltd. | 43 | 1 |
| Laboratoires Thea S.A. | 44 | 1 |
| Lee's Pharmaceutical Holdings Limited | 45 | 1 |
| Lipicard Technologies Limited | 46 | 1 |
| Merck &Co., Inc. | 47 | 1 |
| Mimetogen Pharmaceuticals Inc. | 48 | 1 |
| Mitotech S.A. | 49 | 1 |
| Nanomerics Ltd | 50 | 1 |
| Neuroptis Biotech | 51 | 1 |
| Novaliq GmbH | 52 | 1 |
| Ocular Therapeutix, Inc. | 53 | 1 |
| Oculis ehf | 54 | 1 |
| OncoNOx ApS | 55 | 1 |
| Otsuka Holdings Co., Ltd. | 56 | 1 |
| Parion Sciences, Inc. | 57 | 1 |
| Quorum Innovations LLC | 58 | 1 |
| RegeneRx Biopharmaceuticals, Inc. | 59 | 1 |
| Rigel Pharmaceuticals, Inc. | 60 | 1 |
| Samjin Pharmaceutical Co., Ltd. | 61 | 1 |
| Santen Pharmaceutical Co., Ltd. | 62 | 1 |
| Seikagaku Corporation | 63 | 1 |
| Sucampo Pharmaceuticals, Inc. | 64 | 1 |
| TearSolutions, LLC. | 65 | 1 |
| TopiVert Ltd | 66 | 1 |
| Xigen SA | 67 | 1 |
| Keratoconjunctivitis sicca (Dry Eye) Therapeutics Assessment | 68 | 13 |
| Assessment by Monotherapy Products | 68 | 1 |
| Assessment by Target | 69 | 4 |
| Assessment by Mechanism of Action | 73 | 4 |
| Assessment by Route of Administration | 77 | 2 |
| Assessment by Molecule Type | 79 | 2 |
| Drug Profiles | 81 | 92 |
| AGN-223575 Drug Profile | 81 | 1 |
| AGN-232411 Drug Profile | 82 | 1 |
| Androgen Tears Drug Profile | 83 | 1 |
| AVA-3486 Drug Profile | 84 | 1 |
| AVX-012 Drug Profile | 85 | 1 |
| BRM-421 Drug Profile | 86 | 1 |
| cinhyaluronate sodium Drug Profile | 87 | 1 |
| Cis-Urocanic Acid Drug Profile | 88 | 3 |
| cyclosporine Drug Profile | 91 | 3 |
| cyclosporine Drug Profile | 94 | 2 |
| cyclosporine Drug Profile | 96 | 1 |
| cyclosporine Drug Profile | 97 | 1 |
| cyclosporine Drug Profile | 98 | 1 |
| cyclosporine Drug Profile | 99 | 1 |
| cyclosporine Drug Profile | 100 | 1 |
| cyclosporine Drug Profile | 101 | 1 |
| cyclosporine SR Drug Profile | 102 | 1 |
| dexamethasone acetate SR Drug Profile | 103 | 5 |
| diclofenac sodium Drug Profile | 108 | 1 |
| diquafosol tetrasodium Drug Profile | 109 | 2 |
| disitertide Drug Profile | 111 | 2 |
| Drugs to Agonize FPR2 for Dry Eye Drug Profile | 113 | 1 |
| Elate Ocular Drug Profile | 114 | 1 |
| HL-036 Drug Profile | 115 | 1 |
| HU-007 Drug Profile | 116 | 1 |
| hyaluronate sodium Drug Profile | 117 | 1 |
| ISV-101 Drug Profile | 118 | 1 |
| K-089 Drug Profile | 119 | 1 |
| KeraKlear Drug Profile | 120 | 1 |
| KJ-14003 Drug Profile | 121 | 1 |
| KL-7016 Drug Profile | 122 | 1 |
| KPI-190 Drug Profile | 123 | 1 |
| Lacripep Drug Profile | 124 | 1 |
| LME-636 Drug Profile | 125 | 1 |
| loteprednol etabonate Drug Profile | 126 | 3 |
| LT-4002 Drug Profile | 129 | 1 |
| LT-4003 Drug Profile | 130 | 1 |
| NOP-3 Drug Profile | 131 | 1 |
| NOP-5 Drug Profile | 132 | 1 |
| Nov-03 Drug Profile | 133 | 1 |
| OC-301 Drug Profile | 134 | 1 |
| OX-1001 Drug Profile | 135 | 1 |
| ozagrel Drug Profile | 136 | 1 |
| P-321 Drug Profile | 137 | 2 |
| plastoquinone decyl triphenylphosphonium bromide Drug Profile | 139 | 2 |
| PPL-003 Drug Profile | 141 | 2 |
| Qi-204 Drug Profile | 143 | 1 |
| R-348 Drug Profile | 144 | 2 |
| rebamipide Drug Profile | 146 | 2 |
| Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology Drug Profile | 148 | 2 |
| RGN-259 Drug Profile | 150 | 7 |
| RP-101 Drug Profile | 157 | 1 |
| RU-101 Drug Profile | 158 | 2 |
| SA-001 Drug Profile | 160 | 1 |
| SJP-002 Drug Profile | 161 | 1 |
| Small Molecule to Agonize Glucocorticoid Receptor for Dry Eye Drug Profile | 162 | 1 |
| ST-266 Drug Profile | 163 | 2 |
| tadekinig alfa Drug Profile | 165 | 1 |
| tavilermide hydrochloride Drug Profile | 166 | 2 |
| TOP-1630 Drug Profile | 168 | 1 |
| XG-104 Drug Profile | 169 | 1 |
| ZK-003 Drug Profile | 170 | 1 |
| zucapsaicin Drug Profile | 171 | 2 |
| Keratoconjunctivitis sicca (Dry Eye) Dormant Projects | 173 | 6 |
| Keratoconjunctivitis sicca (Dry Eye) Discontinued Products | 179 | 1 |
| Keratoconjunctivitis sicca (Dry Eye) Product Development Milestones | 180 | 11 |
| Featured News &Press Releases | 180 | 1 |
| Aug 24, 2016: RegeneRx Joint Venture to Begin Second Phase 3 Study Of RGN-259 for Dry Eye Syndrome in 3rd Quarter | 180 | 1 |
| Jul 26, 2016: Parion Sciences Announces Initiation of Phase 2 Clinical Trial of P-321 for the Treatment of Dry Eye Disease | 180 | 1 |
| Jun 07, 2016: Redwood Pharma to Present at BIO 2016 in San Francisco | 181 | 1 |
| May 17, 2016: RegeneRx Releases Letter to Stockholders Regarding its Recent Phase 2/3 Dry Eye Clinical Trial | 181 | 3 |
| May 16, 2016: TopiVert completes preclinical development with TOP1630 for dry eye disease | 184 | 1 |
| May 06, 2016: RGN-259 Confirms Efficacy in Signs and Symptoms of Dry Eye | 184 | 2 |
| May 05, 2016: Novaliq Announces Last Patient Enrolled in Phase 2 Clinical Trial of CyclASol for the Treatment of Moderate to Severe Dry Eye Disease | 186 | 1 |
| May 02, 2016: Parion Sciences Announces the Presentation of Clinical Data on P-321 Ophthalmic Solution for the treatment of Dry Eye Disease at the Association for Research in Vision and Ophthalmology (ARVO 2016) | 186 | 1 |
| Mar 21, 2016: KPI Therapeutics Presents Promising Data on KPI-190 as Potential Therapy for Uveitis, Autoimmune Eye Diseases | 187 | 1 |
| Feb 16, 2016: Novaliq Begins Phase 2 Clinical Trial of CyclASol for the Treatment of Moderate to Severe Dry Eye Disease | 187 | 1 |
| Feb 09, 2016: Fresh Insights Offered Into the Treatment of Severe Keratitis in Dry Eye Disease | 188 | 1 |
| Feb 08, 2016: KPI Therapeutics Initiates Research Program In Eye Diseases | 188 | 1 |
| Jan 29, 2016: RegeneRx Announces Completion of Patient Enrollment In Phase 2b/3 U.S. Dry Eye Trial | 189 | 1 |
| Jan 25, 2016: Portage provides updates on Portage Pharma | 189 | 1 |
| Dec 23, 2015: RegeneRx Joint Venture Posts Results of Severe Dry Eye Trial On ClinicalTrials.gov | 189 | 2 |
| Appendix | 191 | 2 |
| Methodology | 191 | 1 |
| Coverage | 191 | 1 |
| Secondary Research | 191 | 1 |
| Primary Research | 191 | 1 |
| Expert Panel Validation | 191 | 1 |
| Contact Us | 191 | 1 |
| Disclaimer | 192 | 1 |